We supply products to over 25 countries worldwide. Veriton Pharma focuses on the development of licensed medicines, predominantly for CNS, and unlicensed medicines for patients with special requirements that licensed products cannot meet.
The company has a portfolio of more than 60 specialised formulations for treating conditions across a range of therapeutic areas. Veriton Pharma’s products are supported in the UK by a team of Regional Account Managers who are able to access the NHS at all critical levels. Similarly, both the MEA and Australian offices are able to provide experienced sales support within each of these areas.
Unlicensed 'Special' Products
Our heritage of developing tailor-made medications enables Veriton Pharma to provide a range of unlicensed therapy options for those patients whose clinical needs are not met by licensed medications.
News
- SERB Announces the Acquisition of Veriton Pharma
- SAPHNA Annual Conference 2019: HEALTH FOR ALL CHILDREN
SAPHNA Annual Conference 2019: 18th June in Manchester We are delighted to be attending the upcoming SAPHNA Annual Conference; HEALTH FOR ALL CHILDREN – School and Public Health Nurses Turning the Tide…. Read More
- Young Epilepsy online guide for school
Veriton Pharma is pleased to announce the online publication of the charity Young Epilepsy’s online guide for schools. This comprehensive resource aimed at improving the management and support of children with epilepsy… Read More
- Young Epilepsy and Veriton Pharma Ltd announce key partnership agreement in support of the charity’s ‘Rules 4 Schools’ campaign
Young Epilepsy and Veriton Pharma Ltd (Veriton) have announced a key agreement, where the organisations will work in partnership to deliver the ‘Rules 4 Schools” element of the charity’s newly… Read More